Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METHAZOLAMIDE vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
FDA: Adjunctive treatment of open-angle glaucoma or secondary glaucoma; preoperative treatment of acute angle-closure glaucoma.,Off-label: Management of idiopathic intracranial hypertension (pseudotumor cerebri); metabolic alkalosis; acute mountain sickness.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Oral: 50-100 mg two to three times daily.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal half-life: 14-20 hours; approximately 15 hours in adults, prolonged in renal impairment
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Hepatic metabolism via CYP3A4; metabolites include N-demethylated and S-oxidized products.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: 70-90% as unchanged drug; minor biliary/fecal (<10%)
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
~95% bound to plasma proteins (primarily albumin)
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: ~90% (well absorbed); IM: not typically used; IV: 100%
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 10-50 m L/min: Administer every 12 hours; GFR <10 m L/min: Not recommended.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No specific guidelines; use with caution in severe hepatic impairment.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Oral: 5-10 mg/kg/day divided every 6-8 hours; maximum 30 mg/kg/day.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at low end of dosing range due to age-related renal function decline; monitor electrolytes and renal function.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Sulfonamide hypersensitivity reactions; metabolic acidosis; electrolyte disturbances (hypokalemia); drowsiness and confusion; potentiation of acidosis in renal impairment; risk of nephrolithiasis; caution with concomitant use of high-dose aspirin (risk of toxicity).
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hyponatremia or hypokalemia; severe renal or hepatic impairment; adrenal insufficiency; hypersensitivity to sulfonamides or thiazide diuretics; concurrent use with high-dose aspirin.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific food interactions. Maintain adequate hydration. Avoid excessive intake of sodium bicarbonate or antacids containing bicarbonate.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: Crosses placenta; based on animal studies, may cause skeletal and soft tissue malformations. Human data limited but caution advised. Second and third trimesters: Risk of fetal acidosis and electrolyte disturbances due to carbonic anhydrase inhibition. Avoid if possible.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Methazolamide is excreted into breast milk; M/P ratio not established. Potential for metabolic acidosis or sulfonamide-related adverse effects in nursing infant. Use only if benefit outweighs risk; consider alternative agents.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No pharmacokinetic studies in pregnancy; increased glomerular filtration rate may reduce serum levels. Empirical dose adjustment not recommended; monitor clinical effect and adjust as needed.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Methazolamide is a carbonic anhydrase inhibitor used for glaucoma. Monitor serum electrolytes, especially potassium, as hypokalemia is common. Contraindicated in patients with hepatic cirrhosis due to risk of hepatic encephalopathy. Avoid in patients with adrenal insufficiency. Adjust dose in renal impairment. Use with caution in patients with pulmonary obstruction or emphysema as it can cause metabolic acidosis.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take this medication exactly as prescribed, usually twice a day.,You may experience tingling in the fingers or toes, which is common and usually harmless.,Drink plenty of fluids to prevent kidney stones.,Avoid alcohol as it may increase side effects.,Report any signs of infection, easy bruising, or bleeding.,Do not drive or operate heavy machinery until you know how this medication affects you.,This medication may cause sensitivity to sunlight; use sunscreen and protective clothing.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double dose.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"The combination of Triamterene, a potassium-sparing diuretic that inhibits epithelial sodium channels in the distal nephron, with Methazolamide, a carbonic anhydrase inhibitor that reduces renal bicarbonate reabsorption, can lead to severe hyperkalemia and metabolic acidosis due to additive effects on renal electrolyte handling. Both drugs impair renal potassium secretion, while Methazolamide-induced metabolic acidosis further exacerbates hyperkalemia by shifting potassium extracellularly. This synergistic disruption of acid-base balance and potassium homeostasis significantly increases the risk of life-threatening cardiac arrhythmias and neurological impairment."
"Carteolol, a non-selective beta-blocker, can blunt the compensatory sympathetic response to metabolic acidosis induced by methazolamide, a carbonic anhydrase inhibitor. This can lead to excessive bradycardia, hypotension, and potentially precipitate heart failure. The additive effects on lowering intraocular pressure may also be affected."
"Phentermine, a sympathomimetic amine, may competitively inhibit the renal tubular secretion of methazolamide, a carbonic anhydrase inhibitor primarily eliminated via active tubular secretion. This can lead to reduced clearance and increased systemic exposure of methazolamide, potentially elevating its serum levels and prolonging its therapeutic and adverse effects such as metabolic acidosis, paresthesias, and electrolyte imbalances. Clinical outcomes may include increased risk of methazolamide toxicity, particularly in patients with renal impairment, and enhanced diuretic or ocular hypotensive effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METHAZOLAMIDE vs ABSTRAL, answered by our medical review team.
METHAZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METHAZOLAMIDE and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METHAZOLAMIDE is: Oral: 50-100 mg two to three times daily.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METHAZOLAMIDE and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METHAZOLAMIDE is classified as Category C. First trimester: Crosses placenta; based on animal studies, may cause skeletal and soft tissue malformations. Human data limited but caution advised. Second and third trimesters: R. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.